Cocrystal Pharma, Inc. (COCP)

Cocrystal Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	0	0	0	2.01	6.56
Revenue Growth (YoY)	-	-	-	-69.32%	-
Gross Profit	0	0	0	2.01	6.56
Selling, General & Admin	5.99	5.75	5.43	5.57	4.86
Research & Development	15.17	12.39	8.79	6.03	4
Other Operating Expenses	-2.6	20.69	0	0	46.1
Operating Expenses	18.56	38.83	14.22	11.6	54.97
Operating Income	-18.56	-38.83	-14.22	-9.59	-48.41
Interest Expense / Income	0.64	-0	0	0.01	0.02
Other Expense / Income	-1.22	0.01	-0.04	0.05	-0.26
Pretax Income	-17.98	-38.84	-14.19	-9.65	-48.17
Net Income	-17.98	-38.84	-14.19	-9.65	-48.17
Shares Outstanding (Basic)	10	8	7	5	3
Shares Outstanding (Diluted)	10	8	7	5	3
Shares Change	18.52%	10.58%	60.04%	73.32%	13.75%
EPS (Basic)	-1.87	-4.77	-0.16	-2.04	-18.12
EPS (Diluted)	-1.87	-4.77	-0.16	-2.04	-18.12
Free Cash Flow	-14.78	-21.51	-12.77	-10.07	-1.71
Free Cash Flow Per Share	-1.53	-2.64	-1.73	-2.19	-0.64
Gross Margin	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-475.97%	-737.45%
Profit Margin	-	-	-	-479.05%	-733.84%
Free Cash Flow Margin	-	-	-	-500.00%	-26.02%
EBITDA	-17.16	-38.65	-13.99	-9.3	-47.9
EBITDA Margin	-	-	-	-461.97%	-729.68%
Depreciation & Amortization	0.19	0.19	0.19	0.34	0.25
EBIT	-17.34	-38.84	-14.18	-9.64	-48.15
EBIT Margin	-	-	-	-478.65%	-733.55%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).